Publication: Discovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based drug design
Program
KU Authors
Co-Authors
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Source
Publisher
Bentham Science Publishers
Subject
Chemistry
Citation
Has Part
Source
Letters in Drug Design and Discovery
Book Series Title
Edition
DOI
10.2174/1570180810906050337
item.page.datauri
Link
Rights
N/A